Table 3.

Associations with overall survival and clinicopathologic characteristics in TCGA patients using Cox regression, and results of proportional hazards (PH) assumption testing

Characteristics	Total (N)	Univariate analysis			Multivariate analysis
		HR (95% CI)	p-value	PH test p-value	HR (95% CI)	p-value	PH test p-value
Gender	Male vs Female	1.180 (0.885–1.574)	0.261	0.695	–	–	0.695
Weight	> 70 vs < = 70	0.649 (0.389–1.083)	0.098	0.769	–	–	0.769
Height	>= 170 vs < 170	0.855 (0.556–1.316)	0.477	0.161	–	–	0.161
BMI	> 25 vs < = 25	0.827 (0.513–1.333)	0.436	0.346	–	–	0.346
Tumor tissue site	Trunk vs Extremities	0.945 (0.697–1.283)	0.719	0.068	–	–	0.068
	Head and Neck vs Extremities	1.276 (0.760–2.143)	0.357		–	–
	Other vs Extremities	2.113 (1.097–4.067)	0.025		–	–
Radiation therapy	Yes vs No	0.980 (0.696–1.381)	0.909	0.055	–	–	0.055
Age	> 60 vs < = 60	1.663 (1.256–2.201)	< 0.001	0.854	1.088 (0.751–1.576)	0.654	0.854
Pathologic T stage	T2 vs T1	1.523 (0.826–2.806)	0.178	0.695	2.079 (0.933–4.630)	0.073	0.695
	T3 vs T1	2.135 (1.179–3.867)	0.012		1.704 (0.745–3.897)	0.207
	T4 vs T1	3.780 (2.109–6.776)	< 0.001		2.994 (1.094–8.192)	0.033
Pathologic N stage	N1 vs N0	1.503 (1.018–2.220)	0.04	0.769	1.619 (1.007–2.603)	0.047	0.769
	N2 vs N0	1.540 (0.977–2.429)	0.063		2.424 (1.349–4.358)	0.003
	N3 vs N0	2.744 (1.777–4.236)	< 0.001		3.952 (2.201–7.097)	< 0.001
Pathologic M stage	M1 vs M0	1.902 (1.032–3.506)	0.039	0.161	1.362 (0.521–3.560)	0.528	0.161
Breslow depth	> 3 vs < = 3	2.665 (1.948–3.644)	< 0.001	0.346	1.333 (0.688–2.584)	0.394	0.346
Melanoma ulceration	Yes vs No	2.099 (1.506–2.927)	< 0.001	0.591	1.316 (0.883–1.963)	0.178	0.591
Global PH test	–	–	–	–	–	–	0.282